Nanyang Biologics at GITEX ASIA SINGAPORE 2025

From April 23 to 25, 2025, Nanyang Biologics (NYB) participated in GITEX ASIA 2025 at Marina Bay Sands, Singapore. The event, which serves as Asia's premier tech, startup, and digital investment gathering, allowed NYB to present its developments in AI-powered drug discovery and biomanufacturing.

‍

Spotlight on the DTIGN Platform

‍

At exhibition booth, NYB introduced attendees to their proprietary Drug-Target Interaction Graph Neural Network (DTIGN) platform. This AI-driven system leverages advanced graph neural networks to predict molecular bioactivities, aiming to accelerate the identification of bioactive compounds derived from nature. The DTIGN platform represents NYB's commitment to integrating artificial intelligence with biotechnology to revolutionize drug discovery processes.

‍

‍

NYB's innovative approach earned them a spot in the semifinals of the prestigious Supernova Challenge, held at the ELEVATE stage. This competition recognizes groundbreaking startups pushing the boundaries of technology and innovation. NYB's presentation showcased their advancements in AI-driven drug discovery, underscoring their role as a frontrunner in the biotech industry.

‍

‍

Engaging Thought Leadership

‍

NYB's Chief Technology Officer, Giang Nguyen, actively participated in several key sessions during the event. He moderated two dynamic panel discussions on April 23:

‍

• AI in Drug Discovery – Unlocking a $100 Billion Opportunity: This session explored how AI is transforming pharmaceutical R&D, manufacturing, and diagnostics, with insights from industry leaders such as Vishal Doshi (AUM Biosciences), Dr. Lanz Chan (Eves Energy), and Dr. Hari Prasad Kovelamudi (Quality Care India Limited).
• The Genomic Revolution in Precision Medicine: Focusing on the integration of genomics and AI in personalized healthcare, this discussion highlighted the potential for precision medicine to enhance treatment outcomes.

‍

Looking Ahead

‍

Nanyang Biologics' participation in GITEX ASIA 2025 demonstrates our commitment to advancing healthcare through AI and natural compounds. We are actively seeking collaborations with pharmaceutical and healthcare firms to leverage our expertise in AI-driven drug discovery.

‍

By fostering partnerships with global tech leaders and showcasing our cutting-edge technologies, NYB continues to pioneer advancements in healthtech and biomanufacturing.

‍

To stay updated with Nanyang Biologics' latest innovations and announcements, follow us on LinkedIn.

‍

About GITEX ASIA 2025

GITEX ASIA 2025, held at Marina Bay Sands, Singapore from April 23 to 25, stands as Asia's largest and most global tech, startup, and digital investment event. The event brought together over 1,000 exhibitors, 300+ global investors, and 350+ speakers from across the world, focusing on major trends in AI, deep tech, biotech, smart cities, sustainability, and more.

‍

The event served as a powerful platform for innovation, insight sharing, and building transformative partnerships across industries. Featuring multiple stages including the ELEVATE stage for the Supernova Challenge, GITEX ASIA 2025 provided comprehensive coverage of the latest technological advancements and industry developments.

‍

Event highlights included dynamic panel discussions, technology showcases, and networking opportunities for industry leaders, innovators, and investors. The event particularly emphasized the convergence of artificial intelligence with various sectors, including healthcare and biotechnology.